Related Experiment Video
Updated: Aug 18, 2026
Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
Published on: June 9, 2023
Identification of RAI3 as a therapeutic target for breast cancer
1Department of Molecular Biology, Institute of Gerontology, Nippon Medical School, 1-396 Kosugi-cho, Nakahara-ku, Kawasaki 211-8533, Japan. takemitsu.nagahata@nipponkayaku
Abstract:
We have been investigating gene-expression profiles in estrogen receptor (ER)-negative breast cancers to identify molecules involved in breast carcinogenesis and to select genes or gene products that might be useful as diagnostic markers or targets for new molecular therapies. Here we report evidence that the gene encoding retinoic acid-induced protein 3 (RAI3) is a potential molecular target for treatment of breast cancers. Using quantitative reverse transcription-PCR (RT-PCR), we documented increased expression of RAI3 in 19 of 25 primary breast cancers and in 6 of 11 breast-cancer cell lines examined, by comparison with normal mammary-gland tissue. Treatment of human embryonic kidney (HEK293) cells with siRNA against RAI3 suppressed expression of RAI3 and also suppressed cell growth. Transfection of siRNA into breast-cancer cell lines MCF7 and T47D also suppressed RAI3 mRNA and growth of the cancer cells. Because our data imply that up-regulation of RAI3 function is a frequent feature of breast carcinogenesis, we suggest that selective suppression of signal from RAI3 might hold promise for development of a new strategy for treating breast cancers.
Insights
Retinoic acid-induced protein 3 (RAI3) is overexpressed in breast cancers. Suppressing RAI3 inhibits cancer cell growth, suggesting it's a potential therapeutic target for breast cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Gene Expression Profiling
Background:
- Estrogen receptor (ER)-negative breast cancers require identification of novel molecular targets.
- Understanding gene expression is crucial for developing diagnostic markers and targeted therapies.
Purpose of the Study:
- To investigate the role of retinoic acid-induced protein 3 (RAI3) in breast carcinogenesis.
- To evaluate RAI3 as a potential diagnostic marker and therapeutic target for breast cancer.
Main Methods:
- Quantitative reverse transcription-PCR (RT-PCR) to measure RAI3 gene expression.
- Small interfering RNA (siRNA) to suppress RAI3 expression in cell lines.
- Assessment of cell growth inhibition following RAI3 suppression.
Main Results:
- RAI3 expression was elevated in 19/25 primary breast cancers and 6/11 breast cancer cell lines compared to normal tissue.
- siRNA-mediated suppression of RAI3 reduced cell growth in HEK293, MCF7, and T47D cells.
- RAI3 mRNA levels were decreased following siRNA transfection, correlating with growth suppression.
Conclusions:
- Up-regulation of RAI3 is a common feature in breast carcinogenesis.
- Selective suppression of RAI3 signaling presents a promising new therapeutic strategy for breast cancer treatment.
